Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Safety considerations for GLP-1 receptor agonist use in post-bariatric surgery patients require careful attention, as this population may have unique vulnerabilities and altered pharmacokinetics compared to patients without surgical history
hormonal dysregulation, mood disturbances, and recurrent infections are prominent
Ten patients with obesity and type 2 diabetes received weekly subcutaneous semaglutide, escalated from 0.25 mg to 1 mg over 4 weeks and maintained for 8 more weeks (12 weeks total)
However, rapid calorie restriction from appetite suppression can trigger the body to use muscle protein for energy when carbohydrate and fat stores become limited
Retatrutide is the first and only triple receptor agonist to reach Phase 3 clinical trials
